Apr 04, 2025 9:00am EDT Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
Mar 26, 2025 9:05am EDT Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas
Mar 19, 2025 8:50am EDT Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein
Mar 11, 2025 8:45am EDT Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Feb 26, 2025 9:00am EST Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors
Feb 19, 2025 8:35am EST Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates
Feb 18, 2025 9:15am EST Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference
Feb 13, 2025 8:30am EST Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer
